ClinicalTrials.gov record NCT07392411

Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 7, 2026

About this page. This page shows the study's official ClinicalTrials.gov record ↗, with added help to make it easier to understand. We explain medical terms, highlight key details in plain language, and suggest questions you may want to ask the study team.

The record is periodically copied from ClinicalTrials.gov and may lag behind changes. AI summaries are checked by software, not a clinician.Read moreShow less

The official record is written by the study sponsor and published on ClinicalTrials.gov. It may not always reflect the latest changes. Before making any decisions, please confirm important information with the study team and your own healthcare team.

Where you see "AI summary", AI was used to create a plain-language explanation and software checked it against the source. It has not been reviewed by a clinician, so it may contain mistakes or leave out important details.

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.

Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.

Healthy volunteersAcceptedPeople who do not have the condition being studied who are allowed to take part. Some studies include both people with the condition and healthy volunteers; others may enrol only healthy volunteers.

AgeSee eligibility The registry's age field and its own written criteria give different ages for this study. Check the full criteria below and ask the study team.

SexAll

LocationChina

AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This observational study records facial video and speech audio from people with Parkinson's disease, PSP, MSA, and healthy volunteers. AI methods are used to analyze patterns and the AI's scores are compared with human expert ratings. The study aims to create digital biomarkers for diagnosis and disease severity assessment.

What it is studying. The study tests whether artificial intelligence can identify facial-expression and speech features that relate to Parkinson's disease, progressive supranuclear palsy (PSP), and multiple system atrophy (MSA), and whether AI-derived severity or diagnostic scores agree with human expert ratings.

What the researchers hope to learn. To develop and evaluate digital biomarkers based on facial and speech features. To measure the diagnostic accuracy of AI-derived scores by comparing them with human expert ratings. To explore whether facial and speech patterns can help distinguish Parkinson's disease from PSP and MSA.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

This research employs AI to analyze facial expressions and speech patterns, aiming to develop new digital tools for diagnosing and differentiating Parkinson's disease and similar disorders.

Interventions being studied

Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.

Other: video recording

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

Inclusion Criteria for Parkinson's Disease (PD) Group: (1) Diagnostic Criteria: Meet the diagnostic criteria for Parkinson's disease established by the Movement Disorder Society (MDS) in 2015. (2) Age Range: 18-75 years old. (3) Disease Severity: Early-stage PD: Hoehn-Yahr score ≤ 2.5 points. Mid-to-late-stage PD: Hoehn-Yahr score 2.5-5 points. (4) Consent for Data Collection: Willing to undergo facial expression video and speech audio recording. (5) Informed Consent: Signed informed consent form.
Inclusion Criteria for Parkinson's Plus Syndromes (MSA-P, PSP) Group: (1) Age Range: 18-75 years old. (2) Diagnostic Criteria: MSA patients must meet the diagnostic criteria established by the [Chinese Expert Consensus on the Diagnosis of Multiple System Atrophy, 2017]. PSP patients must meet the diagnostic criteria established by the [Chinese Clinical Diagnostic Criteria for Progressive Supranuclear Palsy, 2016 Edition]. (3) Consent for Data Collection: Willing to undergo facial expression video and speech audio recording. (4) Informed Consent: Signed informed consent form.

Exclusion criteria

History of cerebrovascular disease, head trauma, hydrocephalus, brain tumors, or intracranial surgery.
Presence of metal implants, cardiac pacemakers, or other metallic foreign bodies (applies to PD patients).
Severe dyskinesia in PD patients that would compromise cooperation with video/audio recording.
Mini-Mental State Examination (MMSE) score ≤ 24 points.

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

Participants sign informed consent and will undergo cognitive screening (MMSE) and standardized motor assessments where used (MDS‑UPDRS and Hoehn‑Yahr staging are listed for patient groups). They will complete standardized facial video recordings and speech audio recordings. No invasive procedures (for example, lumbar puncture or biopsies) are listed in the record. The recordings and assessment data are used to develop and evaluate AI-based digital measures.

How the study is structured. Observational, cohort, cross-sectional study. Participants undergo standardized facial video and speech audio recording; the recorded data are analyzed by AI and the AI results are compared with expert clinician ratings at baseline.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
The listed sites are in China. Is any of them reachable for me, and does the study help with travel?
Which of the eligibility criteria would need to be checked with tests before I could join?

More on multiple system atrophy

This trial is also listed on this site under progressive supranuclear palsy.

Clinical trials76 trials listed for multiple system atrophyEvery trial the registry lists for multiple system atrophy, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in multiple system atrophy researchLatest monthly update: September 2026. Includes: Tube feeding. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start: Jul 25, 2023
Primary completion: Dec 31, 2026 (estimated)
Study completion: Dec 31, 2026 (estimated)
Target enrollment: 720 participants (estimated)
Last updated on registry: Feb 6, 2026
Data verified: Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor: Beijing Tiantan Hospital

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Lingyan Ma, M.D. 📞 +8613520873987 ✉ Jennifer_MLY@163.com

Participating sites (1)

首都医科大学附属北京天坛医院Recruiting
Beijing, Beijing Municipality, 100070 · China
- Lingyan ma Jennifer, M.D. · 01059976611 · Jennifer_MLY@163.com

Terms used on this page · explanations by MedicalUpdates.ai

Inclusion Criteria: The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Informed Consent: The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
Exclusion Criteria: The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials